<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Children with sickle cell <z:hpo ids='HP_0001903'>anemia</z:hpo> (SCA) and <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> carry a significant risk of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Given the success of encephaloduroarteriosynangiosis (EDAS) or pial synangiosis in the treatment of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya disease</z:e>, the purpose of this study was to examine whether it reliably and durably protected children with SCA and <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> against cerebrovascular complications </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The authors retrospectively reviewed a series of 12 patients with SCA who developed clinical and/or radiological evidence of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> and underwent EDAS </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Eleven patients (92%) presented following a <z:hpo ids='HP_0001297'>cerebrovascular accident</z:hpo> (<z:chebi fb="4" ids="46274">CVA</z:chebi>), <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>), or <z:hpo ids='HP_0001250'>seizure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Magnetic resonance (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) imaging or angiography suggested <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya</z:e> vascular changes, and cerebral angiography confirmed the diagnosis in <z:hpo ids='HP_0000001'>all</z:hpo> 12 patients </plain></SENT>
<SENT sid="5" pm="."><plain>At the time of surgery, the median age was 12.3 years (range 6.8-19.4 years) </plain></SENT>
<SENT sid="6" pm="."><plain>Ten (83%) of 12 patients had a history of <z:chebi fb="4" ids="46274">CVA</z:chebi>, and 4 of these patients were compliant with a transfusion protocol at the time of their <z:chebi fb="4" ids="46274">CVA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Bilateral (7 patients) or unilateral (5 patients) EDAS was performed without complications </plain></SENT>
<SENT sid="8" pm="."><plain>The mean follow-up period was 46.8 months (range 8.1-106 months) </plain></SENT>
<SENT sid="9" pm="."><plain>During the follow-up period, 2 patients (16.7%) suffered cerebrovascular events </plain></SENT>
<SENT sid="10" pm="."><plain>One patient, who was <z:hpo ids='HP_0001297'>stroke</z:hpo>-free preoperatively, suffered a <z:chebi fb="4" ids="46274">CVA</z:chebi> 3 weeks after the procedure </plain></SENT>
<SENT sid="11" pm="."><plain>The other patient suffered a single left lower-extremity <z:hpo ids='HP_0002326'>TIA</z:hpo> 18 months following right-sided EDAS </plain></SENT>
<SENT sid="12" pm="."><plain>She returned to her neurological baseline condition and remains stable 53 months postoperatively </plain></SENT>
<SENT sid="13" pm="."><plain>Seven patients underwent follow-up angiography or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> angiography, and evidence of revascularization was noted in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="14" pm="."><plain>At this time, no patient has developed progressive disease requiring a contralateral procedure after unilateral EDAS </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: The EDAS procedure is a safe and effective treatment option in patients with SCA who develop <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e> </plain></SENT>
</text></document>